<unk>  is a kinase inhibitor that is FDA approved for the treatment of pre/perimenopausal or postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, as initial endocrine-based therapy when given in combination with an aromatase inhibitor; or of postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer, as initial endocrine based therapy or following disease progression on endocrine therapy when given in combination with fulvestrant.   Common adverse reactions include neutropenia, nausea, infections, fatigue, diarrhea, leukopenia, vomiting, alopecia, headache, constipation, rash, and cough.
Ribociclib
Tamoxifen
Trastuzumab
Enzalutamide
Apalutamide
Anastrozole
Lasofoxifene
Stibine